Trials / Completed
CompletedNCT05231746
A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)
A Phase 1, Multicenter, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of hSTC810 Monotherapy in Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- STCube, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The Purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of hSTC810 monotherapy in participants with advanced solid tumors.
Detailed description
The study consists of a dose-escalation phase that will evaluate 6 dosing schedules of hSTC810. The first cohort will be single participant cohort. Subsequent escalation cohorts will use a standard 3+3 design, with the ability to backfill up to an additional 6 patients in each dose cohort.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | hSTC810 | hSTC810 will be administered as an intravenous infusion (IV) |
Timeline
- Start date
- 2022-04-18
- Primary completion
- 2024-02-29
- Completion
- 2024-02-29
- First posted
- 2022-02-09
- Last updated
- 2024-03-13
Locations
5 sites across 2 countries: United States, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05231746. Inclusion in this directory is not an endorsement.